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RAPL (an alternative spliced form of Rassf5) is a
critical Ras-related protein1 (Rap1) effector that
regulates lymphocyte adhesion. Here, we have
shown that in addition to this previously described
function, RAPL also negatively controls lymphocyte
proliferation and prevents autoimmunity and
lymphoma. RAPL-deficient mice experienced age-
related lupus-like glomerulonephritis and developed
B cell lymphomas. RAPL-deficient lymphocytes
showed hyperproliferation by enhanced S phase
entry after antigen receptor ligation. Compared to
wild-type cells, RAPL-deficient naive lymphocytes
had a 2- to 3-fold increase in Cdk2 kinase activity
with a cytoplasmic mislocalization of the cyclin-
dependent kinase inhibitor p27kip1. RAPL was found
to suppress the phosphorylation of p27kip1 on serine
10 (S10) and promoted p27kip1 nuclear translocation.
An S10A mutation in p27kip1 corrected its cyto-
plasmic accumulation, reduced hyperproliferation
in RAPL-deficient lymphocytes, and suppressed
glomerulonephritis and development of B cell
lymphoma. Thus, RAPL serves as a checkpoint for
S phase entry to prevent lymphoproliferative
disorders through the spatial regulation of p27kip1.
INTRODUCTION
The small GTPase Ras-related protein1 (Rap1) regulatesmultiple
functions such as cell proliferation, differentiation, and adhesion
(Bos et al., 2001). RAPL was identified as a Rap1-GTP binding
protein that mediates Rap1 functions by modulating lympho-
cyte function-associated antigen-1 (LFA-1) adhesiveness in24 Immunity 34, 24–38, January 28, 2011 ª2011 Elsevier Inc.concert with cell polarization (Katagiri et al., 2003). RAPL is
predominantly expressed in immune cells, and RAPL-deficient
lymphocytes and dendritic cells have impaired adhesion and
motility triggered by chemokines and defective trafficking to
peripheral lymph nodes, resulting in hypoplastic lymphoid
tissues (Ebisuno et al., 2010; Katagiri et al., 2004). Upon T cell
receptor (TCR) ligation, RAPL also mediates important inside-
out signal downstream of the Src kinase-associated phospho-
protein 1, SKAP-1 (Raab et al., 2010). In previous studies, we
further demonstrated that the Sterile20-like kinase Mst1 is
a downstream effector that mediates LFA-1-dependent lympho-
cyte adhesion upon TCR and chemokine stimulation (Katagiri
et al., 2006, 2009).
Rapl (also known as Nore1b) is an alternative spliced form
of Rassf5, which belongs to a member of the putative tumor-
suppressor Rassf family (Avruch et al., 2009). Nore1A, a longer
isoform of Rassf5 (Rassf5a) has antiproliferative activity in tumor
cell lines (Vos et al., 2003) and epigenetic inactivation of Rassf
members including RASSF5A (previously also known as
NORE1A, which has been reported for various types of cancers)
(Avruch et al., 2009). Although the Rap1 pathways that affect
cell proliferation are thought to be distinct from those that
mediate adhesion (Stork and Dillon, 2005), these studies imply
that RAPL also controls cell proliferation. However, it is not
known whether RAPL regulates cell proliferation in physiological
situations or whether RAPL mutations or silencing lead to
pathological conditions associated with hyperproliferation and
tumor development.
Abnormal cell cycle progression in lymphocytes leads to
excessive activation and proliferation and the subsequent loss
of self tolerance and development of autoimmunity (Balomenos
and Martinez, 2000). Cell cycle progression by cyclins and
cyclin-dependent kinases (Cdks) is tightly regulated by Cdk
inhibitors (CdkIs) (Sherr and Roberts, 1999). A Cdk2 inhibitor,
p27kip1 (encoded by the geneCdkn1b and hereafter p27) (Polyak
et al., 1994) is a critical regulator of cell cycle progression. p27
forms a complex with Cdk2 and suppresses its kinase activity,
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stimulation downregulates p27 through ubiquitination and
subsequent degradation (Appleman et al., 2000). Defective
accumulation of p27 contributes to the induction of T cell anergy
and tolerance (Li et al., 2006a). A deficiency in p27 results in
enlarged lymphoid organs (Fero et al., 1996; Nakayama et al.,
1996). p27 activity is also regulated by subcellular localization
p27 (Ekholm and Reed, 2000). p27 shuttles between the nucleus
and cytoplasm. To exert its inhibitory function, p27 needs to be
transported into the nucleus (Reynisdottir and Massague,
1997). p27 nuclear export is regulated by the exportin CRM1
and ras-related nuclear protein, Ran GTPase, as well as
phosphorylation of p27 on serine 10 (Rodier et al., 2001) by
protein kinases such as kinase interacting stathmin (KIS) (Boehm
et al., 2002), and cytoplasmic translocation of p27 is thought to
prevent the assembly of p27 into cyclin E-Cdk2 complexes
and to impair the antiproliferative effects of p27 (Boehm et al.,
2002; Rodier et al., 2001). Furthermore, genetically targeted
mice bearing a p27 mutant unable to interact with cyclin-Cdks
exhibit a dominant increase in spontaneous tumorigenesis in
many tissues, including lymphomas, compared with Cdkn1b/
mice, indicating an oncogenic function independent of the cy-
clin-Cdks (Besson et al., 2007). The cytoplasmic localization of
p27 in tumor cells, such as B cell lymphomas, has been identified
as a mechanism promoting carcinogenesis in humans and mice
(Barnouin et al., 1999; Qi et al., 2006). However, the physiological
relevance and mechanisms regulating the subcellular localiza-
tion of p27 in lymphocytes are unclear.
Here, we report that RAPL is important in p27 nuclear localiza-
tion in both T and B lymphocytes upon antigen receptor stimula-
tion. As a result, RAPL deficiency caused the mislocalization of
p27 in the cytoplasm and hyperproliferation of both T and B cells.
RAPL-deficient mice developed lupus-like autoimmunity and B
cell lymphomas with high frequencies, suggesting that the regu-
lation of p27 subcellular localization by RAPL serves as a check-
point for S phase entry to prevent immunoproliferative disorders.
RESULTS
Developmentwith Age of Lupus-like Glomerulonephritis
and Lymphoma in RAPL-Deficient Mice
We previously reported that young RAPL-deficient mice
(<2 months) had hypoplastic spleens and peripheral lymph
nodes resulting from reduced lymphocytes. However, approxi-
mately 90% of these mutant female mice, but none of control
littermates, developed enlarged lymph nodes and spleens at
10 months of age. Total B and T cell numbers were increased
by approximately 50%. CD44+CD62L effector-memory T cells
and CD138+B220+ plasma cells increased in 10-month-old
female RAPL-deficient mice compared to littermate controls
(Figure 1A). The aged mutant mice showed a 2-fold increase in
serum IgG concentrations relative to wild-type mice and
also high titers of antibodies to double-strand DNA (dsDNA)
(Figure 1B). Histological examination revealed glomerulone-
phritis, which was associated with the deposits of IgG and C3
as well as proteinuria (Figures 1B and 1C). Although RAPL-defi-
cient male mice showed similar phenotypes, they were evident
at a much later age (15–18 months). There were no significant
differences in Foxp3+CD4+ regulatory T cell populationsbetween wild-type and RAPL-deficient mice (Figure S1 available
online).
In addition, we often found that spleens and lymph nodes in
RAPL-deficient mice were extremely large. Histological and
flow cytometric analyses indicated that RAPL-deficient mice
developed B220+CD19+, diffuse large B cell lymphomas (Figures
1D and 1E). Approximately 30%of RAPL-deficient mice at 1 yr of
age but not in control mice developed B cell lymphomas in the
peripheral lymph nodes and spleens. Further examination of
these lymphomas by flow cytometry indicated that they were
an IgM+, IgD+, CD21+, CD23+, and mature B cell type, and that
progressed lymphomas often lost these markers to various
extents (Figure 1E). They weremonoclonal or oligoclonal in origin
(Figure 1F). B cell lymphomas in RAPL-deficient mice were not
related to the severity of the autoimmune phenotypes.
RAPL-deficient mice also developed tumors in the liver and
lung after 1.5 yr of age, although the frequencies of these tumors
were lower than the lymphomas (Figure S1B). Histologically,
these tumors were identified as hepatocellular carcinomas and
lung adenocarcinomas (Figure S1B).
Enhanced S Phase Entry in RAPL-Deficient
Lymphocytes
To examine whether RAPL deficiency affects proliferative
responses, primary B or T lymphocytes from 7- to 9-week-old
wild-type and RAPL-deficient mice were stimulated by antibody
crosslinking the antigen receptors. Compared to wild-type
B cells, RAPL-deficient B cells displayed enhanced DNA
synthesis with various doses of anti-IgM F(ab0)2 (Figure 2A,
left). Similarly, RAPL-deficient T cells also showed increased
DNA synthesis in response to crosslinking of the TCR complex
in the presence or absence of anti-CD28 (Figure 2A, right).
Consistent with the hyperproliferative response to anti-IgM F
(ab0)2, RAPL-deficient B cells had greater S phase progression
compared to wild-type B cells 48 hr after stimulation (41%
versus 62%) (Figure 2B). Compared to wild-type T cells, RAPL-
deficient T cells also had accelerated S phase entry 48 hr after
anti-CD3 stimulation in the presence or absence of anti-CD28
(8% versus 18%, 20% versus 35%) (Figure 2C). There were no
changes in apoptotic responses after antigen receptor ligation
(data not shown). Thus, RAPL-deficient lymphocytes hyperpro-
liferate in response to antigen receptor ligation.
To demonstrate whether lymphocyte hyperproliferation
occurs in vivo, bromo deoxy uridine (BrdU) was injected intraper-
itoneally into RAPL-deficient mice. As shown in Figure 2D, B cells
and CD4+ T cells as well as CD8+ T cells (data not shown) in
lymph nodes of 10-month-old of RAPL-deficient mice bearing
no malignancies showed increases in incorporation of BrdU
in vivo, compared to those of control lymphocytes, indicating
that RAPL deficiency led to lymphocyte hyperproliferation.
Cell Signaling through Antigen Receptors
in RAPL-Deficient Lymphocytes
We proceeded to investigate the underlying mechanisms of
enhanced lymphocyte proliferation. Because RAPL deficiency
does not affect proliferative signaling pathways mediated by
mitogen-activated protein (MAP) kinase, nuclear factor-kappa
B (NF-kB), or phosphatidyl innositol-3 (PI-3) kinase triggered
by the B cell receptor (BCR) or TCR and/or CD28 (Figure S2A),Immunity 34, 24–38, January 28, 2011 ª2011 Elsevier Inc. 25
Figure 1. Lupus-like Glomerulonephritis and B Cell Lymphomas in RAPL-Deficient Mice
(A) Flow cytometeric profiles of lymphocytes from spleens of wild-type (+/+) and RAPL-deficient (/) mice at 10 months of age. Upper graphs show expression
of CD44 and CD62L on CD4+ gated lymphocytes. Lower graphs show expression of CD138 and B220.
(B) Amounts of serum IgG in 12-month-old wild-type (+/+) and RAPL-deficient (/) mice. p value for RAPL-deficient mice compared to wild-type control is
indicated on the graph (left). Anti-ds DNA titers in 12-month-old wild-type (+/+) and RAPL-deficient (/) mice. p value for RAPL-deficient mice compared to
wild-type control is indicated on the graph (center). Proteinuria in 12-month-old wild-type (+/+) and RAPL-deficient (/) mice. p value for RAPL-deficient
mice compared to wild-type control is indicated on the graph (right). Proteinuria was measured with medical color strips dipped in mouse urine and units
were defined as follows: 0, no proteinuria; 1, 30 mg/dl; 2, 100 mg/dl; 3, 300 mg/dl; 4, 1000 mg/dl.
(C) Glomerulonephritis with immune complex deposits in RAPL-deficient mice. Hematoxlin-Eosin staining (left) and immunostaining with IgG andC3 complement
antibodies (right) of kidney sections from 11-month-old RAPL-deficient mice. Scale bar represents 50 mm.
(D) Low (top) and high (bottom) magnifications of the enlarged lymph nodes from 11-month-old RAPL-deficient mice. Scale bars represent 100 (top) and
10 (bottom) mm, respectively.
(E) Flow cytometric analysis of B cell lymphoma surface phenotypes (B220+, CD19+) developed in RAPL-deficient mice (11 and 15 months old).
(F) Southern blot analysis of Igh locus rearrangement in B cell lymphomas. Approximately 30%of RAPL-deficientmice at 1 yr of age developedB cell lymphoma in
the peripheral lymph nodes or spleens as shown in Figure 7D. Representative B cell lymphomas independently developed in nine RAPL-deficient mice are shown
with tail DNA to indicate the germline (GL) Igh.
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Figure 2. Enhanced Proliferation of RAPL-Deficient Lymphocytes
(A) 3[H]-thymidine uptake by B cells (left) and T cells (right). Primary B and T cells from wild-type (open bar) and RAPL-deficient (closed bar) mice were
unstimulated () or stimulated with antigen receptor ligation by anti-IgM F(ab0)2 at the indicated concentrations, or by anti-CD3 (5 mg/ml) with or without
anti-CD28 (2 mg/ml). 3[H]-thymidine uptake was measured 48 hr after stimulation in triplicate experiments. The mean values and standard errors are shown.
*p < 0.002, **p < 0.01, compared with corresponding wild-type littermate control.
(B and C) Cell cycle profiles of wild-type (+/+) and RAPL-deficient (/) B cells (left) or T cells (right) measured at 48 hr without stimulation () or with antigen
receptor ligation as indicated. The cell populations in each cell cycle phase (G0+G1, S, G2+M)measured by 7AAD and BrdU staining are shownwith percentages
relative to viable cells in each panel. Data are representative of three independent experiments.
(D) BrdU uptake in vivo. Left: Flow cytometric profiles of BrdU-positive cells in B220+ cells and CD4+ cells of 10-month-old wild-type (+/+) and RAPL-deficient
(/) mice. Right: Average percentages and standard errors of BrdU incorporated cells for three wild-type (+/+) and RAPL-deficient (/) mice are shown.
*p < 0.001, compared with wild-type littermate control.
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dent kinase 4 (Cdk4) were upregulated and peaked 48 hr
after stimulation with anti-BCR or anti-CD3 with or without
anti-CD28 (Figure 3A). Cdk4 activity and retinoblastoma (Rb)protein phosphorylation were increased in stimulated B cells
and T cells. RAPL-deficient lymphocytes displayed essentially
the same amounts of upregulation and activation of cyclin D,
Cdk4, and Rb expression and phosphorylation. Similarly, thereImmunity 34, 24–38, January 28, 2011 ª2011 Elsevier Inc. 27
Figure 3. Effects of RAPL Deficiency on Signal Transduction and
Cell Cycle Regulators Downstream of Antigen Receptor Signaling
(A) Expression of cyclin D, Cdk4, Rb, and phospho-Rb measured 48 hr after
antigen receptor ligation in B (left) and T (right) cells from wild-type (+/+) and
RAPL-deficient (/) mice. Total lysates derived from 1 3 105 cells were
applied in each lane. In vitro Cdk4 kinase activities were measured with
GST-Rb as a substrate.
(B) Expression of cyclin E, Cdk2, and its kinase activity measured in vitro via
phosphorylation of histone H1 as a substrate. Expression of p27 and tubulin
in B cells (left) and T cells (right) from wild-type (+/+) and RAPL-deficient
(/) mice 48 hr after antigen receptor ligation. Total lysates from 13 105 cells
were applied in each lane.
(C) Immunostaining of p27 in wild-type (+/+) and RAPL-deficient (/) B and
T cell blasts after stimulation with antigen receptor ligation for 2 days. Repre-
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28 Immunity 34, 24–38, January 28, 2011 ª2011 Elsevier Inc.were no differences in cyclin E and Cdk2 upregulation in both
wild-type andRAPL-deficient T andB cells (Figure 3B). However,
Cdk2 enzymatic activities in RAPL-deficient B and T cells were
augmented at 48 hr compared to wild-type cells after stimulation
with anti-BCR (2.6-fold, 2.4-fold) or anti-TCRwithout (2.5-fold) or
with (2.8-fold) anti-CD28 (Figure 3B). These proliferative
responses were almost completely inhibited by low doses of
a specific Cdk2 inhibitor, CVT-313 (Bhattacharjee et al., 2001),
and RAPL-deficient cells tended to be more sensitive to the
inhibitor (Figure S2B). These results suggest that Cdk2 drives
lymphocyte proliferation and that the enhanced proliferation by
RAPL deficiency is largely dependent on Cdk2 activity.
p27, themajor Cdk inhibitor for Cdk2, is elevated inG0 but then
downregulated by ubiquitination and proteasomal degradation
during the G0 to S phase transition. In B cells stimulated with
anti-BCR, p27 was diminished at 48 hr (Figure 3B). Surprisingly,
p27 was not downregulated in RAPL-deficient B cells after 48 hr
of stimulation with higher anti-BCR concentrations (5.2-fold
compared to wild-type B cells), despite augmented Cdk2 kinase
activities (Figure 3B). In wild-type T cells, p27 was downregu-
lated by anti-CD3 and more efficiently by a combination of
anti-CD3 and anti-CD28 (Figure 3B), and the degradation was
further promoted by the addition of excess amounts of IL-2
(Figure S2C). However, as was the case with RAPL-deficient
B cells, there was little to no decrease in p27 by either anti-CD3
or anti-CD3+anti-CD28 (4.1-fold compared to wild-type T cells)
at 48 hr, although Cdk2 activities were clearly augmented (Fig-
ure 3B). Even excess IL-2 did not promote the degradation of
p27 in RAPL-deficient T cells (Figure S2C), although it promoted
proliferation of wild-type and RAPL-deficient T cells similarly
(data not shown). The amounts of IL-2 in the supernatant of
RAPL-deficient T cells were comparable to those in wild-type
(Figure S2C), ruling out the possibility that reduced p27 degrada-
tion in RAPL-deficient T cells is due to a shortage of IL-2.
Immunostaining of lymphoblasts generated 48 hr after stimu-
lation with antigen receptor ligation revealed that the nuclear p27
was at very low amounts in both WT and RAPL-deficient cells
(Figure 3C). Line-profile analysis showed that 4.4% ± 3.5%
and 12% ± 8.7% of p27 were present in the nucleus of wild-
type B cells and T cells (n = 50), and 5.9% ± 4.7% and
12.6% ± 9.3% in RAPL-deficient B and T lymphoblasts (n = 50)
(Figure S3). p27 accumulated predominantly in the cytoplasm
of RAPL-deficient T and B cells, although a small amount of
p27 remained in the cytoplasm of wild-type cells (Figure 3C;
Figure S3). There were no cells with nuclear dominant patterns
observed in both wild-type or RAPL-deficient lymphoblasts.
Because p27 must be transported into the nucleus to exert
its inhibitory action, the cytoplasmic localization of p27 probablysentative distribution of p27 in lymphocytes is shown. Differential interference
contrast (DIC), p27, and DAPI-stained nuclei are indicated. Scale bars repre-
sent 5 mm.
(D) Subcellular localization and phosphorylation at serine 10 of p27 in B cell
lymphomas. A minimum of 10 independent B cell lymphomas from 10- to
12-month-old RAPL-deficient (/) mice were immunostained with anti-p27
or DAPI (nuclei). All B cell lymphomas showed cytoplasmic localization of
p27, and a representative example is shown (left). Scale bar represents
10 mm. Immunoblot of total and S10 phosphorylated p27 and tubulin in three
independent B cell lymphomas (right).
Figure 4. Deregulation of p27 in RAPL-Deficient Lymphocytes
(A) Defective p27 downregulation in RAPL-deficient B cells. Wild-type (+/+) and RAPL-deficient (/) B cells were stimulated with anti-IgM F(ab0)2 for the indi-
cated times, followed by immunoblot analysis of cyclin E, p27, phosphorylated p27 at threonine 187, Skp2, phosphorylated p27 at serine 10, and tubulin. Total
lysates from 1 3 105 cells were applied in each lane.
(B) Kinetics of p27 phosphorylation at serine 10 (S10) in wild-type (+/+) and RAPL-deficient (/) B cells after anti-IgM stimulation. Total and S10 phosphorylated
p27 and total and phosphorylated Akt are shown. Total lysates from 1 3 105 cells were applied.
(C) Defective p27 downregulation in RAPL-deficient T cells. Wild-type (+/+) and RAPL-deficient (/) T cells were stimulated with anti-CD3 and anti-CD28 for the
indicated times, followed by immunoblot analysis as in (A).
(D) Kinetics of p27 phosphorylation at serine 10 (S10) in wild-type (+/+) and RAPL-deficient T cells (/) after anti-CD3 and anti-CD28 stimulation. Total and S10
phosphorylated p27 and total and phosphorylated Akt are shown. Total lysates from 1 3 105 cells were applied.
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to enhanced Cdk2 activities and resistance to degradation.
In all B cell lymphoma generated in RAPL-deficient mice, p27
was abundantly present in the cytoplasm (Figure 3D), as
observed in BCR-stimulatedRAPL-deficient Bblasts (Figure 3C).
Line-profile analysis showed that 87.6% ± 3.7% of p27 was
present in the cytoplasm. This suggests that the mislocalization
of p27 in the cytoplasm underlies lymphoma development.
Kinetics of Phosphorylation and Degradation
of p27 in RAPL-Deficient Cells
To investigate whether the mislocalization of p27 in the cyto-
plasm underlies lymphoproliferative disorders, we examined
p27 degradation in more detail. In wild-type B and T cells,
p27 declined sharply between 24 and 48 hr after antigenreceptor stimulation (Figures 4A and 4C). Cyclin E increased
after 12–24 hr and was maintained at high amounts at 24–
72 hr. In contrast, RAPL-deficient cells maintained high p27
even at 72 hr poststimulation, whereas cyclin E upregulation
was comparable to that in wild-type cells. T187 phosphorylation
of p27, a trigger of p27 downregulation, was detected in wild-
type cells at 24–72 hr, which coincided with the kinetics of
upregulation of cyclin E and Skp2, a substrate-targeting subunit
of the SCF ubiquitin ligase complex that regulates entry into
S phase (Bashir et al., 2004). RAPL-deficient B and T cells
exhibited comparable Skp2 upregulation and essentially the
same time course of T187 phosphorylation (Figures 4A and
4C). The ratios of p27 phosphorylated on T187 to total p27
were lower in RAPL-deficient B cells (0.42 at 48 hr) and T cells
(0.18 at 48 hr), compared to those of wild-type B cells (0.9 atImmunity 34, 24–38, January 28, 2011 ª2011 Elsevier Inc. 29
Figure 5. Impaired Redistribution of p27 in RAPL-Deficient B and T Lymphocytes after Antigen Receptor Stimulation
(A and B) Primary lymphocytes from the lymph nodes of wild-type (+/+) and RAPL-deficient (/) mice were stained for p27, B220, and CD3. The number of cells
with a cytoplasmic and nuclear distribution p27 were visualized and counted by confocal microscopy. At least 100 cells were counted in different microscopic
fields. Representative images of p27, B220, CD3, DIC, and DAPI in wild-type cells and average percentages and standard errors for three independent exper-
iments are shown (B). Scale bar represents 5 mm.
(C) Redistribution of p27 in wild-type (+/+) (left) and RAPL-deficient (/) (right) B cells. Primary B cells were stimulated with anti-IgM for the indicated times and
stained for p27 and nuclei (DAPI). Note that in wild-type B cells, cytoplasmic p27 was translocated into nuclei 2 hr after stimulation before degradation (left), but in
RAPL-deficient B cells, cytoplasmic p27 failed to localize in nuclei (right). Scale bars represent 5 mm.
(D) High magnification of cytoplasmic and nuclear distribution of p27 in wild-type (+/+) and RAPL-deficient (/) B cells 2 hr after stimulation are shown. Line
profiles of p27 and DAPI along the arrows are shown in Figure S5. The average percentages of cells showing nuclear- (open bar) or cytoplasmic- (closed bar)
dominant p27 staining in three independent experiments are shown in the lower panel. A minimum of 100 cells were scored per treatment group. *p < 0.001,
compared with corresponding wild-type littermate control. Scale bar represents 5 mm. The percentages of the nuclear fraction of p27 in the nuclear- and
cytoplasmic-dominant population of wild-type B cells were 78.6% ± 6.9% and 36.1% ± 5.5%, and those of RAPL-deficient B cells were 58.5% ± 4.9% and
21.8% ± 2.4%. The difference in the percentages of nuclear p27 between nuclear- and cytoplasmic-dominant population was statistically significant (p < 0.002).
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Lymphoproliferative Diseases in RAPL-Deficient Mice48 hr) and T cells (0.22 at 72 hr) (Figures 4A and 4C). The
decreased phosphorylation on T187 of p27 might reflect cyto-
plasmic accumulation of p27 in RAPL-deficient lymphoblasts
(Figure 3C; Figure S3), because T187 was mainly phosphory-
lated by Cdk2-cyclinE in the nucleus (Hara et al., 2001; Lee
and Kay, 2007). These data suggest that RAPL deficiency does
not affect T187 phosphorylation and Skp2-dependent proteol-
ysis of p27 in the nucleus.
Serine 10 (S10), the major phosphorylation site of p27 (Ishida
et al., 2000), is required for cytoplasmic localization at the
G0-G1 transition in response to mitogenic stimulation (Rodier
et al., 2001). S10 phosphorylation was high in resting wild-type
B cells, declined to the lowest amounts at 2 and 12 hr poststim-
ulation, and were subsequently undetectable as p27 was
degraded (Figure 4A). Resting RAPL-deficient B cells showed
similar amounts of S10 phosphorylation; however, S10 phos-
phorylation did not decrease at 2 and 12 hr poststimulation
and were maintained in high amounts levels even at 72 hr (Fig-
ure 4A), as well as that of cytoplasmic p27 in B cell lymphoma
(Figure 3D). We also examined S10 phosphorylation at early
time points after stimulation. In wild-type B cells, S10 phosphor-
ylation was decreased as early as 5 min after stimulation and
further declined thereafter (Figure 4B). In contrast, S10 phos-
phorylation was relatively constant with a slight increase at
10 min in RAPL-deficient B cells (Figure 4B). There were no
differences in Akt and Erk phosphorylation in wild-type and
RAPL-deficient B cells (Figures 4B; Figure S2A), ruling out the
involvement of these kinases in elevated S10 phosphorylation
in RAPL-deficient B cells.
T cells showed different magnitudes and patterns of S10
phosphorylation compared to B cells. The S10 phosphorylation
in resting T cells were lower than those in resting B cells. S10
phosphorylation was augmented at 12 and 24 hr poststimulation
with anti-CD3+anti-CD28 (Figure 4C). RAPL-deficient T cells
exhibited similar kinetics of S10 phosphorylation, with approxi-
mately 2-fold higher amounts (Figure 4C). When kinetic
experiments were performed at early time points, S10 phosphor-
ylation was transiently increased at 5–10 min and returned to
basal levels 30 min after anti-CD3 and anti-CD28 stimulation
(Figure 4D). RAPL-deficient T cells displayed similar, transient
but enhanced S10 phosphorylation (Figure 4D). Stimulation
with anti-CD3 alone induced S10 phosphorylation almost
comparable to that by anti-CD3 and anti-CD28 (Figure S4A),
indicating that phosphorylation of p27 at S10 is mainly regulated
through TCR signaling. Thus, enhanced phosphorylation on
S10 occurs at 5–10 min and 12–24 hr after stimulation in
RAPL-deficient T cells, which precedes degradation of p27
and the entry to S phase. Again, there were no changes in Akt
and Erk phosphorylation in RAPL-deficient T cells (Figure 4D;(E) Redistribution of p27 in wild-type (+/+) (left) and RAPL-deficient (right) T cells.
times and stained for p27 and nuclei (DAPI), as in (C). Note that a portion of nuclear
RAPL-deficient T cells, but cells showing predominantly cytoplasmic p27 increas
sents 5 mm.
(F) The average percentages of cells showing nuclear- (open bar) or cytoplasmic-
type (+/+) and RAPL-deficient T cells were stimulated for 2 hr or 20 hr with anti-C
0.005, compared with corresponding wild-type littermate control. The percentag
wild-type T cells were 62.5% ± 5.6% and 17.9% ± 11.3%, and those of RAPL-d
percentages of cytoplasmic p27 between cytoplasmic- and nuclear-dominant pFigure S2A). Collectively, these results suggest that RAPL defi-
ciency specifically upregulates S10 phosphorylation that is
important for the cytoplasmic localization of p27 in lymphocytes.
Because IL-7 has been reported to stimulate proliferation
through enhanced p27 destabilization in an IL-7-dependent
thymocyte cell line (Li et al., 2006b), we examined the effect of
IL-7 on S10 phosphorylation. IL-7 augmented proliferation of
T cells from wild-type and RAPL-deficient mice to the same
extent (approximately 4-fold) in the presence of anti-CD3
(Figure S4B). IL-7 did not affect S10 phosphorylation in both
wild-type and RAPL-deficient T cells (Figure S4C), indicating
that IL-7 enhanced proliferation independently of RAPL.
Mislocalization of p27 in the Cytoplasm
of RAPL-Deficient Cells
We next examined p27 redistribution in primary lymphocytes by
immunostaining. Unexpectedly, resting T and B lymphocytes
exhibited distinct p27 distribution patterns: in B cells p27 was
predominantly cytoplasmic (83.5% ± 3% of p27), but in T cells,
the majority of p27 was localized in the nucleus (94.2% ± 1.2%
of p27) (Figure 5A). Quantitative results showed that the distribu-
tion of p27 in the cytoplasm was essentially the same in resting
wild-type and RAPL-deficient B cells (Figure 5B). Similar to
wild-type T cells, most RAPL-deficient T cells also showed
nuclear localization of p27with aminor population showing cyto-
plasmic localization (Figure 5B).
After anti-BCR stimulation, p27 was dynamically redistributed
in wild-type B cells. p27 rapidly clustered in the cytoplasm near
the nucleus 20 min after stimulation and relocated into the
nucleus at 2 hr (Figure 5C). Quantitative analysis showed that
p27 distribution was predominantly nuclear in approximately
40% of the population at 2 hr (Figure 5D; Figure S5A). At 20 hr,
the amount of p27 in the nucleus decreasedwith some remaining
in the cytoplasm (Figure 5C; Figure S5B). In RAPL-deficient
B cells, p27 also rapidly clustered in the cytoplasm (Figure 5C).
However, in more than 80% of cells, p27 failed to localize to
the nucleus at 2 hr and remained abundant in the cytoplasm at
20 hr (Figures 5C and 5D; Figure S5). Preferential decrease of
p27 in the nucleuswith residual p27 in the cytoplasm of wild-type
B cells suggested that p27 degradation occurs mostly in the
nucleus and that RAPL deficiency impaired a step in p27 nuclear
translocation in B cells. The subcellular location of p27 is consis-
tent with S10 phosphorylation kinetics and amounts.
Although a majority of p27 was present in the nucleus of
resting wild-type T cells, a fraction of p27 was also cytoplasmic
in most T cells 20 min after anti-CD3 and anti-CD28 stimulation,
and 20% of the T cells exhibited the cytoplasmic-dominant
distribution of p27 at 2 hr (Figures 5E and 5F). Meanwhile,
the cytoplasmic-dominant population was almost doubledPrimary T cells were stimulated with anti-CD3 and anti-CD28 for the indicated
p27was translocated into the cytoplasm after stimulation in both wild-type and
ed in RAPL-deficient T cells compared with wild-type T cells. Scale bar repre-
(closed bar) dominant p27 in three independent experiments are shown. Wild-
D3+anti-CD28. A minimum of 100 cells were scored per treatment group. *p <
es of cytoplasmic p27 in the cytoplasmic and nuclear-dominant population of
eficient T cells were 66.1% ± 6.0% and 25.6% ± 15.2%. The difference in the
opulation was statistically significant (p < 0.001).
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Figure 6. RAPL Promotes p27 Nuclear Localization and Suppresses S Phase Entry
(A) RAPL mutant did not inhibit p27 phosphorylation on S10. 293T cells with or without RAPL or RAPLDN expression were serum starved for 2 days and
then stimulated with 10% serum for 5 hr. Total and S10 phosphorylated p27, myc-RAPL or myc-RAPLDN, and tubulin are shown. Total lysates derived from
1 3 104 cells were applied in each lane.
(B) Inhibition of p27 nuclear export by RAPL but not RAPLDN. 293T cells were transfected with GFP alone (), RAPL, or RAPLDN plus GFP (green) and then
stimulated with serum for 5 hr after serum starvation for 2 days. Cells were immunostained for p27 (red) and DAPI (nuclei). Scale bar represents 10 mm.
(C) Cell cycle analysis of 293T cells without () or with RAPL or RAPLDN expression before or after serum stimulation for 20 hr. The percentage of cells labeled
with BrdU (S phase) is shown in each panel. The results are representative of three independent experiments.
(D) Cell cycle analysis of control or p27-specific shRNA transfected 293T cells without () or with RAPL expression before or after serum stimulation for
20 hr. The percentage of cells labeled with BrdU (S phase) is shown in each panel. The results are representative of three independent experiments
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5E and 5F). The similar increase in the cytoplasmic-dominant
distribution was observed in RAPL-deficient T cells at 2 hr after
stimulation with anti-CD3 alone (data not shown). Thus, these
results indicate the possibility that RAPL modulates the cyto-
plasmic localization of p27 through S10 phosphorylation.Inhibition of p27 S10 Phosphorylation and Enhanced
Nuclear Localization by RAPL
To examine whether RAPL modulates S10 phosphorylation and
subcellular localization of p27, we employed a heterologous
system by using 293T cells, which are well characterized for
nuclear export of p27 (Boehm et al., 2002; Ishida et al., 2002).
S10 was basally phosphorylated in serum-starved 293T cells,
increased at 0.5 hr after serum stimulation, and then peaked
at 1–5 hr to amounts similar to that in continuously growing cells
(Figure S6A). In contrast, in serum-starved RAPL-transfected
293T cells, basal and serum-induced S10 phosphorylation was
severely diminished (Figure S6A). In loss-of-function mutant lack-
ing the N-terminal half (RAPLDN) (Katagiri et al., 2003)-transfected
293T cells, serum-induced S10 phosphorylation was not
decreased (Figure 6A). At 5 hr after serum addition, 51.2% ±
3.1% of p27 was cytoplasmic in control cells. Under the same
conditions, 82.2% ± 7.4% of p27 was nuclear in RAPL-
expressing cells with very low amounts in the cytoplasm, but this
effect was not observed in RAPLDN-expressing cells (Figure 6B),
consistent with the S10 phosphorylation amounts of p27 (Fig-
ure 6A). RAPL, but not RAPLDN expression, reduced the
frequency of cells in S phase at 20 hr after serum stimulation (Fig-
ure6C). This reductionwasabrogatedbyp27silencing (Figure6D),
indicating that the inhibitory effect of RAPL on proliferation
depends on p27.
We also confirmed the similar effects of RAPL on p27 localiza-
tion by using CH27 B cell lymphoma cells. RAPL expression
promoted nuclear localization and significantly decreased cell
proliferation (Figure S6B). This suppressive effect of RAPL on
proliferation was also abrogated by p27 silencing (Figure S6B).
If RAPL could promote nuclear localization of p27 through
suppression of S10 phosphorylation, cytoplasmic localization
of a phosphomimetic mutant p27S10D (Ishida et al., 2000)
should not be affected by RAPL. To examine this possibility,
Flag-tagged p27 and p27S10D were transfected into control
and RAPL-expressing cells. The cells were synchronized by
serum starvation, then added to serum for 6 hr before staining.
Wild-type p27 was localized in the cytoplasm of control cells,
whereas it was mainly present in the nucleus of RAPL-express-
ing cells, as is the case with endogenous p27 (Figure 6E). In
contrast, approximately 90% of p27S10D was localized in the
cytoplasmof both control andRAPL-expressing cells (Figure 6E),
indicating that S10D is dominant over RAPL for p27 localization.
This provides further support for the notion that RAPL regulates
p27 localization through suppression of S10 phosphorylation.(left). Immunoblot of p27 and tubulin in RAPL or vector control () expressing
(right).
(E) A S10D mutation of p27 inhibited the nuclear localization of p27 by RAP
p27 together with GFP alone () or RAPL plus GFP (green), and then stimulat
nostained for flag (red) and DAPI (nuclei). Scale bar represents 10 mm.Because kinase interacting stathmin (KIS) was reported to
phosphorylate S10 in the G1 phase (Boehm et al., 2002), we
investigated whether RAPL could inhibit KIS kinase activity.
The Flag-tagged mouse KIS and RAPL were cotransfected into
293 T cells, and we examined immune-complex kinase activity
of KIS by using p27 and p27S10A protein as a substrate. KIS
phosphorylated the wild-type p27 but not the p27 mutant in
which serine 10 is substituted with alanine (p27S10A) (Fig-
ure S6C), as reported (Boehm et al., 2002). RAPL expression
reduced the kinase activity of KIS on S10 by 60% (Figure S6C).
Meanwhile, silencing of KIS in 293T cells increased nuclear-
dominant localization of p27, as previously reported (Boehm
et al., 2002), and RAPL overexpression had marginal effects on
the nuclear localization of p27 in KIS-silenced 293T cells (data
not sown). This result suggests that RAPL could decrease the
phosphorylation of p27 on S10 at least through the suppression
of KIS activity.
The S10AMutation in p27kip1 Suppresses Autoimmunity
and B Cell Lymphoma in RAPL-Deficient Mice
If the growth stimulatory effect of RAPL deficiency is mediated
by S10 phosphorylation of p27, it would be expected that the
S10A mutation could counteract its effect and prevent lympho-
proliferative diseases of RAPL-deficient mice. To examine this
possibility, we crossed p27S10A genetically targeted mice
(Kotake et al., 2005) with RAPL-deficient mice to generate
Cdkn1bS10A/S10A RAPL-deficient mice (Figure 7A). As shown in
Figure 7B, the S10A mutation in p27 significantly reduced the
CD138+B220+ plasma cells by 67% and CD44+CD62L
effector-memory T cells by 28%. Accordingly, the titers of
antibodies to double-stranded DNA (dsDNA) decreased by
58%, the incidence of proteinuria was reduced (63% versus
22%), and also deposition of IgG was rarely detected (Figure 7C;
Figure S7A), indicating that the S10A mutation suppressed the
development of severe glomerulonephritis in 10-month-old
RAPL-deficient mice. Importantly, B cell lymphoma and other
tumors did not develop in Cdkn1bS10A/S10A RAPL-deficient
mice (Figure 7D; Figure S7B).
In resting Cdkn1bS10A/S10A B cells sufficient or deficient for
RAPL, p27 was mainly located in the cytoplasm as seen in the
wild-type situation, although its distribution tended to be
aggregated near the nucleus (Figure 7E). In Cdkn1b+/+ RAPL-
deficient B cells, p27 remained in the cytoplasm after stimulation
(Figure 5C). In contrast, when Cdkn1bS10A/S10A RAPL-deficient
B cells were stimulated with anti-IgM, p27S10A translocated
into the nucleus in both RAPL-sufficient and -deficient B cells
with comparable numbers of cells showing nuclear-dominant p27
(Figure 7E; Figure S7C). p27 degradation in Cdkn1bS10A/S10A
RAPL-deficient B cells was greatly accelerated compared to
that of Cdkn1b+/+ RAPL-deficient B cells (Figure S7D), and the
level of degradation was almost equivalent to that of wild-type
B cells (Figure 3B). Cdkn1bS10A/S10A RAPL-deficient B cells did
not exhibit enhanced proliferation with anti-IgM, compared to293T cell lysates after control-(c) or p27-specific (p27) shRNA transfection
L. 293T cells were transfected with flag-tagged wild-type or S10D mutant
ed with serum for 5 hr after serum starvation for 2 days. Cells were immu-
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B cells (Figure 7E). Thus, S10A mutation corrected B cell
abnormalities.
In Cdkn1bS10A/S10A T cells sufficient or deficient for RAPL, p27
was mainly located in the nucleus, as is the case with Cdkn1b+/+
T cells (Figure 7F). When stimulated with anti-CD3 and anti-
CD28, the proportion of the cells expressing p27S10A translo-
cated into the cytoplasm was lower than that of the cells with
wild-type p27 (21.4% versus 33.1%) (Figure 7F; Figure S7C).
There was no significant increase of RAPL-deficient T cells
with cytoplasmic-dominant localization of p27S10A (20.6%)
(Figure 7F; Figure S7C). p27 degradation in Cdkn1bS10A/S10A
RAPL-deficient T cells was also enhanced compared to that of
Cdkn1b+/+ RAPL-deficient T cells (Figure S7D), and the amount
of downregulation was almost equal to that of wild-type T cells
(Figure 3B). The cytoplasmic mislocalization of p27 in Cdkn1b+/+
RAPL-deficient T cells with anti-CD3 was also corrected with
S10A mutation on p27 (Figure S7E). These results indicate that
the mislocalization and degradation of p27 in RAPL-deficient
T cells was dependent on S10 phosphorylation. T cells from
Cdkn1bS10A/S10A RAPL-deficient T cells exhibited lower prolifer-
ation compared to Cdkn1b+/+ RAPL-deficient T cells, but it was
still significantly higher than Cdkn1bS10A/S10A RAPL-sufficient
T cells (Figure 7F). These data suggest that hyperproliferation
of T cells by RAPL deficiencywas partly dependent on S10 phos-
phorylation, although other mechanisms are probably involved.
All together, these results demonstrate that RAPL-dependent
regulation of phosphorylation of p27 on S10 plays important
roles for prevention of lupus-like glomerulonephritis and B cell
lymphoma.
DISCUSSION
Our results demonstrated a role for RAPL in suppression of S10
phosphorylation of p27 and nuclear export of p27, thereby
retarding the G1-S phase transition. The defective checkpoint
in the G1-S transition resulting from RAPL deficiency enhancedFigure 7. Effects of S10A Mutation on RAPL-Deficient Mice
(A) Expression of RAPL, p27, phospho-S10 of p27, and tubulin in B cells derive
Cdkn1bS10A/S10ARassf5exon3/exon3 mice.
(B) The ratios of CD138+ and B220+ lymphocytes (top left) or CD44+ a
Cdkn1b+/+Rassf5exon3+/exon3+, Cdkn1b+/+Rassf5exon3/exon3, and Cdkn1bS10A/S1
expression of CD138 and B220 (top right) and CD44 and CD62L on CD4+ gated
(C) Anti-double-strand DNA titers in 12-month-old Cdkn1b+/+Rassf5exon3+/exon3+
Proteinuria in 12-month-old mice (right). Proteinuria was measured with medica
to Cdkn1b+/+Rassf5exon3/exon3 mice are indicated on the graph. *p < 0.02, **p
(D) Development of B cell lymphomas inCdkn1b+/+Rassf5exon3+/exon3+,Cdkn1b+/+R
of age. Lymph nodes and spleens from 20 mice per each group were subjected
(E) Left: The S10A mutation abrogated mislocalization of p27 with anti-IgM
Cdkn1bS10A/S10ARassf5exon3+/exon3+, and Cdkn1bS10A/S10ARassf5exon3/exon3 mic
for p27 and nuclei (DAPI). Scale bars represent 5 mm. Right: The S10A mutation
3[H]-thymidine uptake by B cells. Primary B from Cdkn1b+/+Rassf5exon3+/exon3+,
Cdkn1b+/+Rassf5exon3/exon3 mice were unstimulated () or stimulated with ant
(F) Left: The S10A mutation corrected mislocalization of p27 with anti-CD3 and
Cdkn1bS10A/S10ARassf5exon3+/exon3+, and Cdkn1bS10A/S10ARassf5exon3/exon3 mic
stained for p27 and nuclei (DAPI). Scale bars represent 5 mm. Right: The S10A
with anti-CD3 and anti-CD3+CD28. 3[H]-thymidine uptake by T cells. Prima
Cdkn1bS10A/S10ARassf5exon3/exon3, and Cdkn1b+/+Rassf5exon3/exon3 mice
*p < 0.01, **p < 0.03.proliferation, leading to lupus-type glomerulonephritis and
lymphomas. p27S10A genetic targeting in the RAPL-deficient
background rescued both glomerulonephritis and B cell
lymphoma and demonstrates that S10 phosphorylation of p27
is critical for the development of lymphoproliferative diseases
by RAPL deficiency.
Our results suggest that mislocalized p27 leads to increased
Cdk2 activity, which in turn promotes G1-S phase transition in
lymphocytes. It was reported that Cdc2 plays a role in S-phase
entry in the absence of Cdk2 (Aleem et al., 2005). p27 also
associates with and inhibits Cdc2 (Aleem et al., 2005). The exper-
imentwithaCdk2 inhibitor favors themajor role ofCdk2 inSphase
entryofnormal lymphocytes,althoughprolongedCdk2deficiency
might lead tocompensationwithCdc2. Ineither case, it ispossible
that RAPL suppresses both Cdk2 and Cdc2 activity through the
promotion of p27 nuclear localization and regulates S phase entry
of lymphocytes after stimulation through antigen receptors.
The S10 mutation of p27 completely abrogated the hyperpro-
liferative responses of RAPL-deficient B cells, but partially
inhibited those of RAPL-deficient T cells, indicating that other
mechanisms operate in RAPL-deficient T cells. Mst1 is activated
by Rap1 and RAPL and responsible for Rap1- and RAPL-depen-
dent integrin regulation (Katagiri et al., 2006, 2009). Mst1 is also
involved in T cell proliferation (Avruch et al., 2009; Katagiri et al.,
2009). Proliferative responses were augmented in Mst1/
T cells, but not B cells (Avruch et al., 2009; Katagiri et al.,
2009). However, p27 regulation in Mst1/ lymphocytes was
found to be normal (unpublished data). Thus, Mst1 differently
regulates lymphocyte proliferation independently of p27, and
hyperproliferative responses observed in Cdkn1bS10A/S10A
RAPL-deficient T cells might be due to defective activation of
Mst1 by RAPL deficiency.
This study shows that KIS appears to be a relevant target of
RAPL during the G1-S transition, because KIS phosphorylates
S10 during the G1 phase in response to mitogenic stimulation
and promotes its nuclear export (Boehm et al., 2002). Interest-
ingly, KIS was reported to play important roles in cell cycled from Cdkn1b+/+Rassf5exon3+/exon3+, Cdkn1bS10A/S10ARassf5exon3+/exon3+, and
nd CD62L on CD4+ gated lymphocytes (bottom left) from spleens of
0ARassf5exon3/exon3 mice at 10 months of age. Flow cytometric profiles of
lymphocytes (bottom right). *p < 0.02, **p < 0.05.
, Cdkn1b+/+Rassf5exon3/exon3, and Cdkn1bS10A/S10ARassf5exon3/exon3 (left).
l color strips. p values for Cdkn1bS10A/S10Rassf5exon3/exon3 mice compared
< 0.01.
assf5exon3/exon3, andCdkn1bS10A/S10ARassf5exon3/exon3mice at 12months
for histological examination.
F(ab0)2. Redistribution of p27 in B cells from Cdkn1b
+/+Rassf5exon3+/exon3+,
e. Primary B cells were stimulated with anti-IgM F(ab0)2 for 2 hr and stained
abrogated hyperproliferation of RAPL-deficient B cells with anti-IgM F(ab0)2.
Cdkn1bS10A/S10ARassf5exon3+exon3/+, Cdkn1bS10A/S10ARassf5exon3/exon3, and
i-IgM F(ab0)2 at concentrations indicated.
anti-CD28. Redistribution of p27 in T cells from Cdkn1b+/+Rassf5exon3+/exon3+,
e. Primary T cells were stimulated with anti-CD3 and anti-CD28 for 2 hr and
mutation decreased hyperproliferative responses of RAPL-deficient T cells
ry T from Cdkn1b+/+Rassf5exon3+/exon3+, Cdkn1bS10A/S10ARassf5exon3+/exon3+,
were unstimulated () or stimulated with anti-CD3 and anti-CD3+CD28.
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phosphorylation of p27 (Nakamura et al., 2008), suggesting an
important role of KIS in lymphoid cells. However, multiple
kinases besides KIS were also reported to phosphorylate p27
at S10 including Cdk5 (Kawauchi et al., 2006), suggesting
a complex network of redundant kinases controlling p27 degra-
dation and cell cycle progression in vivo. It will be important to
examine whether RAPL could regulate KIS and other kinase
activities in lymphocytes.
The importanceofRAPLregulation in thecell cycle is supported
by the incidence of lupus-like glomerulonephritis disease.
Although RAPL-deficient mice are lymphopenic at a young age,
both RAPL-deficient T and B cells are activated and differentiate
into effector-memory T cells and plasma cells with age. In a lym-
phopenic state, self-antigens provide proliferation-inducing
signals that expand T cells until the T cell pool is reestablished
to a nearly normal size (Lawson et al., 2001). It is conceivable
that a lymphopenic state resulting fromdefective lymphocyte traf-
ficking in RAPL-deficientmice favors homeostatic proliferation of
self-reactive clones, which predisposes mice to autoimmune
disease. IL-7 is critical for homeostatic proliferation together
with signals from the TCR recognizing a complex of self-peptides
and MHC (Jacobs et al., 2010; Tan et al., 2001). IL-7 might help
expanding self-reactive clones in RAPL-deficient mice.
Enhanced lymphocyte proliferation probably increases the
developmentof spontaneousBcell lymphomas inRAPL-deficient
mice. RAPL-deficient mice also developed lung and liver tumors
after 1.5 yr of age, suggesting a tumor-suppressor function for
RAPL in nonlymphoid organs, despite low RAPL expression in
these tissues. There are several studies showing that cytoplasmic
p27 is associated with hyperproliferation and tumorigenesis
through a cyclin-Cdk-independent function (Besson et al., 2006,
2007). Cytoplasmic mislocalization of p27 might underlie the
development of spontaneous tumors in RAPL-deficient mice. It
was also reported that the NORE1B (RASSF5C) gene was
frequently inactivated in human hepatocellular carcinomas
because of promoter methylation (Macheiner et al., 2006). It will
be interesting to study involvement of downregulation of RAPL
in human hyperproliferative autoimmune andmalignant diseases.
Our findings that RAPL, a molecule originally identified as an
integrin regulator, also plays an inhibitory role in cell proliferation
provides a molecular link with cell adhesion and growth. In line
with this notion, a constitutively active LFA-1 was found to be
rather inhibitory to antigen-induced proliferation (Semmrich
et al., 2005). Rap1 and p27 were previously reported to be
involved in T cell anergy (Boussiotis et al., 2000). Recent studies
suggest that cytoplasmic p27 can inhibit cell migration behaviors
by binding to Rho or stathmin (Baldassarre et al., 2005). Further
characterization of these processes will facilitate our under-
standing on the link between cell adhesion and proliferation
thorough RAPL. Our studies provide important clues and exper-
imental systems to elucidate how disruption of coordinated
regulation of adhesion and proliferation leads to autoimmunity
and carcinogenesis.EXPERIMENTAL PROCEDURES
Plasmids, antibodies, and reagents are described in Supplemental Experi-
mental Procedures.36 Immunity 34, 24–38, January 28, 2011 ª2011 Elsevier Inc.Mice
RAPL-deficient mice were generated by targeting the RAPL-specific exon3 of
Rassf5 as previously described (Katagiri et al., 2004). Homozygous mice and
littermate control mice were crossed with wild-type C57BL/6 mice for eight
generations. Mice were housed in specific-pathogen-free conditions and all
experiments were in accordance with protocols approved by the Animal
Care and Use Committee of Kansai Medical University (Osaka, Japan). p27
genetically targeted mice harboring an S10A mutation were generated as
previously described (Kotake et al., 2005).
Immunoprecipitation, Immunoblot, and In Vitro Kinase Assays
Immunoprecipitation and immunoblot were performed as described in
Supplemental Experimental Procedures. Signals of appropriate bands were
quantified with an image analyzer (BAS-1500, Fujifilm). Kinase assays for
Cdk2 and Cdk4 were performed as described before (Nakayama et al.,
1996). In brief, immunoprecipitates with rabbit anti-Cdk2 or anti-Cdk4 from
cell lysates from T or B cells stimulated with anti-IgM (Fab0)2 or anti-CD3 and
anti-CD28 were washed with lysis buffer (Nonidet P-40, 150 mM NaCl,
25mMTris-HCl [pH 7.4], 10%glycerol) and suspended in 30 ml of kinase buffer
(50 mM HEPES [pH 7.4], 10 mM MgCl2, 1 mM DTT, 10 mM b-glycerophos-
phate) containing 1 mg Histone H1 (Calbiochem) or 0.5 mg GST-Rb (Santa-
Cruz) and 25 mM ATP, 10 mCi [g-32P]ATP (6000 Ci/mmol, Amersham). The
samples were incubated at 30C for 30 min, denatured in SDS sample buffer,
and run on a 15% SDS-polyacrylamide gel (Nakayama et al., 1996). Kinase
assays of KIS were done with GST-p27 and GST-p27S10A, as described
(Boehm et al., 2002). The signals from appropriate bands were quantified
with a phosphoimager (BAS3000, Fujifilm) and fold-increase was calculated
after background subtraction.
Immunostaining
Immunostaining procedures are described in Supplemental Experimental
Procedures. Confocal images were obtained with a LSM510 META micro-
scopewith a 633 objective lens. Line profiles of cells stained for p27 and nuclei
(DAPI) were used to measure nuclear/cytoplasmic p27 distribution (see
Supplemental Experimental Procedures and Figure S3 for details). Cell surface
staining and analysis with a FACSCalibur (Beckton-Dickinson) flow cytometer
were previously described (Katagiri et al., 2004). For immunohistochemistry of
kidney tissues to detect IgG and C3 deposition, paraffin sections were dew-
axed, blocked with diluted horse serum, and then stained with FITC-goat
anti-mouse IgG and C3.
Cell Proliferation and BrdU Incorporation Assays
B and T lymphocytes purified from spleens or lymph nodes were cultured
at 1.5 3 105/ml in 0.2 ml per well of a 96-well plate with or without anti-IgM
F(ab0)2 or anti-CD3(5 mg/ml and CD28 (2 mg/ml) for 48 hr. [
3H]-thymidine
(1 mmCi/well) was added for the last 6 hr. Cells were harvested and [3H]-thymi-
dine uptake was measured. To determine the frequency and nature of
individual cells that synthesized DNA during culture, BrdU incorporation was
performed with a BrdU flow kit according to the manufacturer’s instruction
(BD PharMingen). BrdU uptake in vivo is described in Supplemental Experi-
mental Procedures.
Statistical Analysis
Student’s two-tailed t test was used to compare experimental groups. p values
less than 0.05 were considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at doi:10.1016/
j.immuni.2010.12.010.
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